Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort

Journal of Bone and Mineral Research

Volumn 28, Issue 3, 2013, Pages 442-448

  Misof, Barbara M ^a   Roschger, Paul ^a   Gabriel, Daniela ^a   Paschalis, Eleftherios P ^a   Eriksen, Erik F ^b   Recker, Robert R ^c   Gasser, Jürg A ^d   Klaushofer, Klaus ^a  

^a AUVA Soziale Unfallversicherung   (Austria)

^b AKER UNIVERSITY HOSPITAL   (Norway)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

BONE MINERALIZATION DENSITY DISTRIBUTION; HORIZON PIVOTAL FRACTURE TRIAL; qBEI; QUANTITATIVE BACKSCATTERED ELECTRON IMAGING; TRANSILIAC BIOPSY; ZOLEDRONIC ACID

Indexed keywords

BIOLOGICAL MARKER; CALCIUM; PLACEBO; ZOLEDRONIC ACID;

ARTICLE; BONE BIOPSY; BONE DENSITY; BONE MASS; BONE MINERALIZATION; BONE TURNOVER; CORTICAL BONE; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MORPHOMETRICS; TRABECULAR BONE;

BIOPSY; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DIPHOSPHONATES; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; PLACEBOS;

EID: 84873975316     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1780     Document Type: Article

References (31)

1. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF., Cummings SR; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007 May 3; 356 (18): 1809-22.
2. Compston J., Treatments for osteoporosis: looking beyond the HORIZON. N Engl J Med. 2007 May 3; 356 (18): 1878-80.
3. Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, Cummings SR, Delmas PD, Palermo L, Mesenbrink P., Cauley JA; HORIZON Pivotal Fracture Trial. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab. 2009 Sep; 94 (9): 3215-25.
4. Eastell R, Lang T, Boonen S, Cummings S, Delmas PD, Cauley JA, Horowitz Z, Kerzberg E, Bianchi G, Kendler D, Leung P, Man Z, Mesenbrink P, Eriksen EF., Black DM; HORIZON Pivotal Fracture Trial. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporos Int. 2010 Jul; 21 (7): 1277-85.
5. Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, García-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF., Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res. 2008 Jan; 23 (1): 6-16.
6. Roschger P, Paschalis EP, Fratzl P, Klaushofer K., Bone mineralization density distribution in health and disease. Bone. 2008; 42: 456-66.
7. Roschger P, Gupta HS, Berzlanovich A, Ittner G, Dempster DW, Fratzl P, Cosman F, Parisien M, Lindsay R, Nieves JW, Klaushofer K., Constant mineralization density distribution in cancellous human bone. Bone. 2003; 32: 316-23.
8. Ruffoni D, Fratzl P, Roschger P, Klaushofer K, Weinkamer R., The bone mineralization density distribution as a fingerprint of the mineralization process. Bone. 2007; 40: 1308-19.
9. Ruffoni D, Fratzl P, Roschger P, Phipps R, Klaushofer K, Weinkamer R., Effect of temporal changes in bone turnover on the bone mineralization density distribution: a computer simulation study. J Bone Miner Res. 2008; 23: 1905-14.
10. Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K., Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone. 2001; 29 (2): 185-91.
11. Zoehrer R, Roschger P, Fratzl P, Durchschlag E, Paschalis E, Phipps R, Klaushofer K., Effects of 3- and 5-year treatment with risedronate on the bone mineral density distribution of cancellous bone in human iliac crest biopsies. J Bone Miner Res. 2006; 21: 1106-12.
12. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ., Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. 2000; 27: 687-94.
13. Boivin G, Meunier PJ., Effects of bisphosphonates on matrix mineralization. J Musculoskelet Neuronal Interact. 2002; 2: 538-43.
14. Borah B, Dufresne TE, Ritman EL, Jorgensen SM, Liu S, Chmielewski PA, Phipps RJ, Zhou X, Sibonga JD, Turner RT., Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone. 2006; 39: 345-52.
15. Nuzzo S, Lafage-Proust MH, Martin-Badosa E, Boivin G, Thomas T, Alexandre C, Peyrin F., Synchrotron radiation microtomography allows the analysis of three-dimensional microarchitecture and degree of mineralization of human iliac crest biopsy specimens: effect of etidronate treatment. J Bone Miner Res. 2002; 17: 1372-82.
16. Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster DW, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilezikian J, Lindsay R., Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab. 2003; 88 (3): 1150-6.
17. Roschger P, Manjubala I, Zoeger N, Meirer F, Simon R, Li C, Fratzl-Zelman N, Misof BM, Paschalis EP, Streli C, Fratzl P, Klaushofer K., Bone material quality in transiliac bone biopsies of postmenopausal osteoporotic women after 3 years of strontium ranelate treatment. J Bone Miner Res. 2010; 25 (4): 891-00.
18. Roschger P, Fratzl P, Eschberger J, Klaushofer K., Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies. Bone. 1998; 23: 319-26.
19. Misof BM, Bodingbauer M, Roschger P, Wekerle T, Pakrah B, Haas M, Kainz A, Oberbauer R, Mühlbacher F, Klaushofer K., Short-term effects of high-dose zoledronic acid treatment on bone mineralization density distribution after orthotopic liver transplantation. Calcif Tissue Int. 2008; 83: 167-75.
20. Recker RR, Kimmel DB, Parfitt AM, Davies KM, Keshawarz N, Hinders S., Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females. J Bone Miner Res. 1988 Apr; 3 (2): 133-44.
21. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ., Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997; 100: 1475-80.
22. Ebeling PR, Burr DB., Positive effects of intravenous zoledronic acid on bone remodeling and structure: are different effects on osteoblast activity to other oral bisphosphonates responsible?. J Bone Miner Res. 2008; 23: 2-5.
23. Gamsjaeger S, Buchinger B, Zwettler E, Recker R, Black D, Gasser JA, Eriksen EF, Klaushofer K, Paschalis EP., Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly zoledronic acid. J Bone Miner Res. 2011; 26: 12-8.
24. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH., Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006; 38: 617-27.
25. Roschger P, Dempster DW, Zhou H, Paschalis EP, Silverberg SJ, Shane E, Bilezikian JP, Klaushofer K., New observations on bone quality in mild primary hyperparathyroidism as determined by quantitative backscattered electron imaging. J Bone Miner Res. 2007; 22: 717-23.
26. Misof BM, Gamsjaeger S, Cohen A, Hofstetter B, Roschger P, Stein E, Nickolas T, Rogers H, Dempster D, Zhou H, Recker R, Lappe J, McMahon D, Paschalis E, Fratzl P, Shane E, Klaushofer K., Bone material properties in premenopausal women with idiopathic osteoporosis. J Bone Miner Res. Epub. 2012 Jul 6: DOI: 10.1002/jbmr.1699.
27. Bonewald LF., The amazing osteocyte. J Bone Miner Res. 2011; 26: 229-38.
28. Atkins GJ, Findlay DM., Osteocyte regulation of bone mineral: a little give and take. Osteoporos Int. 2012 Aug; 23 (8): 2067-79.
29. Brennan O, Kennedy OD, Lee TC, Rackard SM, O'Brien FJ., Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis. J Orthop Res. 2011; 29: 419-24.
30. Recker RR, Kimmel DB, Dempster D, Weinstein RS, Wronski TJ, Burr DB., Issues in modern bone histomorphometry. Bone. 2011; 49: 955-64.
31. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez R, Tan M, Ruzycky ME, Su G, Eastell R., The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012 Feb; 27 (2): 243-54.